Hiroaki Ikesue

1.4k total citations
69 papers, 988 citations indexed

About

Hiroaki Ikesue is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Hiroaki Ikesue has authored 69 papers receiving a total of 988 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 12 papers in Pharmacology. Recurrent topics in Hiroaki Ikesue's work include Nausea and vomiting management (7 papers), Pharmacy and Medical Practices (7 papers) and Cancer Treatment and Pharmacology (7 papers). Hiroaki Ikesue is often cited by papers focused on Nausea and vomiting management (7 papers), Pharmacy and Medical Practices (7 papers) and Cancer Treatment and Pharmacology (7 papers). Hiroaki Ikesue collaborates with scholars based in Japan and United States. Hiroaki Ikesue's co-authors include Ryozo Oishi, Takahisa Yano, Nobuaki Egashira, Takehiro Kawashiri, Tohru Hashida, Nobuyuki Muroi, Yuki Mihara, Toshiaki Sendo, Keisuke Tomii and Yoshinori Itoh and has published in prestigious journals such as SHILAP Revista de lepidopterología, Pain and Annals of Oncology.

In The Last Decade

Hiroaki Ikesue

65 papers receiving 966 citations

Peers

Hiroaki Ikesue
Michael Böhm Germany
Dolores B. Njoku United States
Fu‐Mei Chung Taiwan
Meixiao Sheng China
Martin H. J. Wiesen Germany
Lian‐Sheng Wang China
Ruwen Böhm Germany
Tomohiro Mizuno Japan
Fatma Hümeyra Yerlikaya Türkiye
Michael Böhm Germany
Hiroaki Ikesue
Citations per year, relative to Hiroaki Ikesue Hiroaki Ikesue (= 1×) peers Michael Böhm

Countries citing papers authored by Hiroaki Ikesue

Since Specialization
Citations

This map shows the geographic impact of Hiroaki Ikesue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Ikesue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Ikesue more than expected).

Fields of papers citing papers by Hiroaki Ikesue

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Ikesue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Ikesue. The network helps show where Hiroaki Ikesue may publish in the future.

Co-authorship network of co-authors of Hiroaki Ikesue

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Ikesue. A scholar is included among the top collaborators of Hiroaki Ikesue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Ikesue. Hiroaki Ikesue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hotta, T, Keizo Fukushima, Kei Irie, et al.. (2024). Effect of Hematopoietic Stem Cell Transplantation Regimen on Tacrolimus Pharmacokinetics. Current Therapeutic Research. 102. 100775–100775.
3.
Irie, Kei, Nobuhiro Hiramoto, Hiroaki Ikesue, et al.. (2023). Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma. Investigational New Drugs. 41(5). 761–767. 4 indexed citations
4.
Irie, Kei, Nobuyuki Fukui, Hirotoshi Imamura, et al.. (2023). Pharmacokinetics of Temozolomide in a Patient With Glioblastoma Undergoing Hemodialysis: A Short Communication. Therapeutic Drug Monitoring. 45(6). 823–826.
5.
Ikesue, Hiroaki, et al.. (2022). Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. Cancer Chemotherapy and Pharmacology. 89(6). 833–838. 6 indexed citations
6.
Ikesue, Hiroaki, Kei Irie, Toshinari Yamasaki, et al.. (2022). Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide. Frontiers in Pharmacology. 13. 901099–901099. 4 indexed citations
7.
Ikesue, Hiroaki, et al.. (2021). Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemotherapy and Pharmacology. 87(6). 871–877. 14 indexed citations
8.
9.
Ikesue, Hiroaki, Hideaki Tomita, Nobuyuki Muroi, et al.. (2021). Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Supportive Care in Cancer. 29(8). 4763–4772. 27 indexed citations
10.
Tanaka, Mizuki, Yu Yoshida, Shiori Hasegawa, et al.. (2021). Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database. Frontiers in Pharmacology. 12. 692292–692292. 6 indexed citations
11.
Ikesue, Hiroaki, Yoshio Masuda, Nobuyuki Muroi, et al.. (2020). Evaluation of the usefulness of protocol‐based pharmacist‐facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer. Journal of Clinical Pharmacy and Therapeutics. 45(6). 1288–1294. 7 indexed citations
12.
Hasegawa, Shiori, Hiroaki Ikesue, Satoshi Nakao, et al.. (2020). Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiology and Drug Safety. 29(10). 1279–1294. 27 indexed citations
13.
Fujimoto, Ayumi, Keizo Fukushima, Kei Irie, et al.. (2020). Population pharmacokinetics of tacrolimus in umbilical cord blood transplant patients focusing on the variation in red blood cell counts. Journal of Clinical Pharmacy and Therapeutics. 46(1). 190–197. 3 indexed citations
14.
Uchida, Mayako, Yuki Yamaguchi, Hiroaki Ikesue, et al.. (2020). Risk Factors for Febrile Neutropenia Induced by Docetaxel Chemotherapy in Patients with Non-small Cell Lung Cancer. Biological and Pharmaceutical Bulletin. 43(8). 1235–1240. 7 indexed citations
15.
Nakao, Satoshi, Shiori Hasegawa, Mizuki Tanaka, et al.. (2020). Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. International Journal of Medical Sciences. 17(7). 921–930. 7 indexed citations
16.
Ikesue, Hiroaki, Tohru Nagano, & Tohru Hashida. (2018). A Case of Acute Kidney Injury Associated With Dabrafenib and Trametinib Treatment for Metastatic Melanoma. Annals of Pharmacotherapy. 52(10). 1051–1052. 4 indexed citations
17.
Ikesue, Hiroaki, et al.. (2018). Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery. Journal of Pharmaceutical Health Care and Sciences. 4(1). 13–13. 4 indexed citations
18.
Ikesue, Hiroaki, Kazumi Fujita, Hobyung Chung, et al.. (2018). Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. Journal of Pharmaceutical Health Care and Sciences. 4(1). 17–17. 6 indexed citations
19.
Watanabe, Hiroyuki, Hiroaki Ikesue, Kenichiro Nagata, et al.. (2013). Decrease in Venous Irritation by Adjusting the Concentration of Injected Bendamustine. Biological and Pharmaceutical Bulletin. 36(4). 574–578. 3 indexed citations
20.
Ikesue, Hiroaki. (2006). Development of Work Sheets to Provide Efficient Pharmaceutical Care during Cancer Chemotherapy and Their Evaluation. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 32(1). 1–12. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Böhm Breakdown of academic impact, for papers by Dolores B. Njoku Breakdown of academic impact, for papers by Fu‐Mei Chung Breakdown of academic impact, for papers by Meixiao Sheng Breakdown of academic impact, for papers by Martin H. J. Wiesen Breakdown of academic impact, for papers by Lian‐Sheng Wang Breakdown of academic impact, for papers by Ruwen Böhm Breakdown of academic impact, for papers by Tomohiro Mizuno Breakdown of academic impact, for papers by Fatma Hümeyra Yerlikaya
Rankless by CCL
2026